{
  "label": "spec",
  "artifact_type": "scope_spec",
  "artifact_id": "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
  "input_ids": [
    "sha256:18337e265501ea2852bb2f7648860e251703ab998faf12668ece880515dc7b74"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T11:53:46.507871",
  "content": "{\n  \"scope_id\": \"clinical_signal_03\",\n  \"domain\": \"clinical_notes\",\n  \"description\": \"Weekly clinical trial site summaries revealing drug-drug interaction hepatotoxicity signal\",\n  \"generation\": {\n    \"temperature\": 0.7,\n    \"seed\": 303\n  },\n  \"episodes\": {\n    \"count\": 30,\n    \"timeline\": {\n      \"start\": \"2024-03-04\",\n      \"interval\": \"7d\"\n    },\n    \"format\": \"Weekly clinical trial site summary with enrollment counts, lab panels (ALT/AST/bilirubin/ALP), adverse event logs, concomitant medications, and protocol deviation notes\",\n    \"target_words\": 500\n  },\n  \"scenario\": {\n    \"setting\": \"A Phase III multi-site trial for a novel anti-inflammatory compound\\n(LNS-4821) across 12 clinical sites. Weekly site summaries include:\\nenrollment/randomization counts, lab panels (hepatic: ALT, AST,\\nbilirubin, ALP; renal: creatinine, BUN; hematology: WBC, platelets),\\nadverse event logs with severity grading, concomitant medication\\nlists, and protocol deviation reports. A drug-drug interaction\\nwith concomitant statin therapy (atorvastatin) causes hepatotoxicity\\nin a subpopulation. Liver enzymes creep up in statin co-administered\\npatients before the SAE threshold is reached.\\n\",\n    \"voice\": \"Clinical shorthand. Structured lab data with units and reference\\nranges. CRF-style entries. Adverse events graded by CTCAE.\\nTerse investigator notes. No narrative interpretation.\\n\"\n  },\n  \"arc\": [\n    {\n      \"id\": \"baseline\",\n      \"episodes\": \"1-8\",\n      \"description\": \"Trial enrollment ramp-up. 180 subjects randomized across sites. Lab panels within normal limits (ALT 15-35 U/L, AST 18-32 U/L, bilirubin 0.4-0.9 mg/dL). Mild AEs (headache, GI). Concomitant meds documented including statins in ~30% of subjects.\",\n      \"signal_density\": \"none\"\n    },\n    {\n      \"id\": \"early_signal\",\n      \"episodes\": \"9-15\",\n      \"description\": \"Subtle hepatic signal emerging in statin subgroup. ALT creeping to 45-65 U/L in statin co-administered patients while non-statin patients remain normal. AST following similar pattern. Individual values below 3x ULN so no protocol-mandated action. Site-level aggregates mask the subgroup pattern.\",\n      \"signal_density\": \"low\"\n    },\n    {\n      \"id\": \"red_herring\",\n      \"episodes\": \"14-16\",\n      \"description\": \"Site 07 lab equipment calibration issue flagged. Several elevated ALT values attributed to instrument drift at Site 07. Data management requests re-assay. Investigation focuses on site-level contamination hypothesis, distracting from the cross-site statin subgroup pattern.\",\n      \"signal_density\": \"medium\"\n    },\n    {\n      \"id\": \"escalation\",\n      \"episodes\": \"16-22\",\n      \"description\": \"Statin subgroup ALT reaching 80-120 U/L (2-3x ULN). Two subjects meet Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN). SAE reports filed. Non-statin patients remain stable. Pattern visible across multiple sites, not just Site 07. Protocol amendment under discussion.\",\n      \"signal_density\": \"high\"\n    },\n    {\n      \"id\": \"root_cause\",\n      \"episodes\": \"23-30\",\n      \"description\": \"Drug-drug interaction confirmed: LNS-4821 inhibits CYP3A4 metabolism of atorvastatin, causing statin accumulation and hepatotoxicity. Cross-site analysis shows ALT elevation correlates with statin co-administration, not site. DSMB reviews data. Protocol amended to exclude statin co-administration.\",\n      \"signal_density\": \"high\"\n    }\n  ],\n  \"noise\": {\n    \"description\": \"Normal clinical trial operations \\u2014 screen failures, routine protocol deviations, minor AEs, site monitoring visits, supply shipments, regulatory correspondence\",\n    \"examples\": [\n      \"Screen failure SF-0142: exclusion criterion #4 (eGFR <60)\",\n      \"Protocol deviation PD-031: missed visit window (2 days late), minor\",\n      \"AE-0089: headache, Grade 1, possibly related, resolved\",\n      \"Site 03 monitoring visit completed, 2 minor findings\",\n      \"IP resupply shipped to Sites 04, 08, 11\"\n    ]\n  },\n  \"distractors\": {\n    \"count\": 90,\n    \"target_words\": 500,\n    \"themes\": [\n      {\n        \"id\": \"renal_biomarker_study\",\n        \"scenario\": \"A Phase II renal biomarker validation study. Weekly site\\nsummaries tracking novel urinary biomarkers (KIM-1, NGAL,\\ncystatin C) against traditional eGFR. Dose-response\\nassessment in diabetic nephropathy patients.\\n\",\n        \"excluded_terms\": [\n          \"hepatotoxicity\",\n          \"ALT\",\n          \"AST\",\n          \"bilirubin\",\n          \"statin\",\n          \"atorvastatin\",\n          \"CYP3A4\",\n          \"Hy's Law\",\n          \"liver enzyme\"\n        ]\n      },\n      {\n        \"id\": \"vaccine_immunogenicity\",\n        \"scenario\": \"A Phase I/II vaccine immunogenicity trial. Weekly summaries\\ntracking antibody titers (IgG, IgM, neutralizing Ab),\\nT-cell responses (CD4/CD8), injection site reactions,\\nseroconversion rates across dose cohorts.\\n\",\n        \"excluded_terms\": [\n          \"hepatotoxicity\",\n          \"ALT\",\n          \"AST\",\n          \"bilirubin\",\n          \"statin\",\n          \"atorvastatin\",\n          \"CYP3A4\",\n          \"Hy's Law\",\n          \"liver enzyme\"\n        ]\n      },\n      {\n        \"id\": \"pain_management_trial\",\n        \"scenario\": \"A Phase III chronic pain management trial comparing\\nmultimodal analgesia. Weekly summaries tracking VAS pain\\nscores, opioid morphine equivalents, functional assessments\\n(6MWT, grip strength), sleep quality indices, rescue\\nmedication use.\\n\",\n        \"excluded_terms\": [\n          \"hepatotoxicity\",\n          \"ALT\",\n          \"AST\",\n          \"bilirubin\",\n          \"statin\",\n          \"atorvastatin\",\n          \"CYP3A4\",\n          \"Hy's Law\",\n          \"liver enzyme\"\n        ]\n      }\n    ],\n    \"seed\": 399,\n    \"max_similarity\": 0.3\n  },\n  \"key_facts\": [\n    {\n      \"id\": \"statin_subgroup_alt\",\n      \"fact\": \"ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases\",\n      \"first_appears\": \"early_signal:2\",\n      \"reinforced_in\": [\n        \"early_signal:5\",\n        \"escalation:2\",\n        \"root_cause:3\"\n      ]\n    },\n    {\n      \"id\": \"cross_site_pattern\",\n      \"fact\": \"multi-site signal distribution rules out site-specific confounders as causal explanation\",\n      \"first_appears\": \"escalation:3\",\n      \"reinforced_in\": [\n        \"escalation:5\",\n        \"root_cause:2\"\n      ]\n    },\n    {\n      \"id\": \"ddi_mechanism\",\n      \"fact\": \"the hepatic enzyme pattern is consistent with a drug-drug interaction mediated through shared hepatic metabolism pathways, not direct hepatotoxicity\",\n      \"first_appears\": \"escalation:4\",\n      \"reinforced_in\": [\n        \"root_cause:1\",\n        \"root_cause:4\"\n      ]\n    },\n    {\n      \"id\": \"site07_red_herring\",\n      \"fact\": \"Site 07 lab equipment issue is not the cause of ALT elevations\",\n      \"first_appears\": \"red_herring:2\",\n      \"reinforced_in\": [\n        \"escalation:3\"\n      ]\n    },\n    {\n      \"id\": \"renal_function_normal\",\n      \"fact\": \"the adverse signal is hepatic (ALT/AST elevation), not renal \\u2014 kidney function markers remain stable while liver enzymes diverge\",\n      \"first_appears\": \"baseline:4\",\n      \"reinforced_in\": [\n        \"early_signal:3\",\n        \"escalation:4\"\n      ]\n    },\n    {\n      \"id\": \"immune_markers_normal\",\n      \"fact\": \"the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns\",\n      \"first_appears\": \"baseline:5\",\n      \"reinforced_in\": [\n        \"early_signal:4\"\n      ]\n    },\n    {\n      \"id\": \"pain_endpoints_stable\",\n      \"fact\": \"musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver\",\n      \"first_appears\": \"baseline:6\",\n      \"reinforced_in\": [\n        \"early_signal:5\"\n      ]\n    },\n    {\n      \"id\": \"alt_temporal_onset\",\n      \"fact\": \"ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event\",\n      \"first_appears\": \"escalation:2\",\n      \"reinforced_in\": [\n        \"escalation:5\",\n        \"root_cause:3\"\n      ]\n    }\n  ],\n  \"questions\": [\n    {\n      \"id\": \"cs03_q01_longitudinal\",\n      \"checkpoint_after\": 12,\n      \"type\": \"longitudinal\",\n      \"prompt\": \"Based on the trial data so far, are there any emerging safety signals in the lab panels?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"ALT values are creeping upward in a subset of patients, specifically those on concomitant statin therapy. The elevations are still below protocol action thresholds but the trend across multiple weeks is notable.\",\n        \"key_facts\": [\n          \"statin_subgroup_alt\",\n          \"cross_site_pattern\",\n          \"alt_temporal_onset\",\n          \"renal_function_normal\",\n          \"pain_endpoints_stable\"\n        ],\n        \"evidence\": [\n          \"early_signal:2\",\n          \"early_signal:5\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q02_null\",\n      \"checkpoint_after\": 12,\n      \"type\": \"null_hypothesis\",\n      \"prompt\": \"What was the enrollment count at Site 03 in the Week 6 summary?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"The enrollment figure as documented in the Week 6 site summary.\",\n        \"key_facts\": [],\n        \"evidence\": [\n          \"baseline:6\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q03_longitudinal\",\n      \"checkpoint_after\": 25,\n      \"type\": \"longitudinal\",\n      \"prompt\": \"What is driving the hepatic adverse events in this trial?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"A drug-drug interaction between LNS-4821 and concomitant statin therapy (atorvastatin) via CYP3A4 inhibition. The hepatotoxicity signal is in the statin subgroup across all sites, not a site-specific lab issue. The Site 07 equipment hypothesis was a red herring.\",\n        \"key_facts\": [\n          \"statin_subgroup_alt\",\n          \"cross_site_pattern\",\n          \"ddi_mechanism\",\n          \"site07_red_herring\",\n          \"renal_function_normal\"\n        ],\n        \"evidence\": [\n          \"early_signal:2\",\n          \"escalation:3\",\n          \"root_cause:1\",\n          \"red_herring:2\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q04_action\",\n      \"checkpoint_after\": 30,\n      \"type\": \"action_recommendation\",\n      \"prompt\": \"What protocol amendments should the DSMB recommend?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"Exclude concomitant statin use from the trial. Add CYP3A4 interaction screening. Implement more frequent hepatic panel monitoring for enrolled subjects. Consider dose adjustment studies for the LNS-4821/statin interaction.\",\n        \"key_facts\": [\n          \"ddi_mechanism\",\n          \"statin_subgroup_alt\",\n          \"pain_endpoints_stable\"\n        ],\n        \"evidence\": [\n          \"escalation:4\",\n          \"root_cause:1\",\n          \"root_cause:4\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q05_negative\",\n      \"checkpoint_after\": 15,\n      \"type\": \"negative\",\n      \"prompt\": \"Is there evidence of nephrotoxicity or renal dysfunction in enrolled subjects?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"No. Renal panels (creatinine, BUN, eGFR) remain within normal limits throughout the trial. The emerging safety signal is hepatic, not renal.\",\n        \"key_facts\": [\n          \"renal_function_normal\",\n          \"statin_subgroup_alt\"\n        ],\n        \"evidence\": [\n          \"baseline:4\",\n          \"early_signal:3\"\n        ]\n      },\n      \"expected_answer_polarity\": \"negative\"\n    },\n    {\n      \"id\": \"cs03_q06_paraphrase\",\n      \"checkpoint_after\": 25,\n      \"type\": \"paraphrase\",\n      \"prompt\": \"Why are liver enzymes elevated in a subset of trial participants?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"A drug-drug interaction between LNS-4821 and concomitant statin therapy (atorvastatin) via CYP3A4 inhibition. The hepatotoxicity signal is in the statin subgroup across all sites, not a site-specific lab issue. The Site 07 equipment hypothesis was a red herring.\",\n        \"key_facts\": [\n          \"statin_subgroup_alt\",\n          \"cross_site_pattern\",\n          \"ddi_mechanism\",\n          \"site07_red_herring\"\n        ],\n        \"evidence\": [\n          \"early_signal:2\",\n          \"escalation:3\",\n          \"root_cause:1\",\n          \"red_herring:2\"\n        ]\n      },\n      \"variant_of\": \"cs03_q03_longitudinal\"\n    },\n    {\n      \"id\": \"cs03_q07_temporal\",\n      \"checkpoint_after\": 25,\n      \"type\": \"temporal\",\n      \"prompt\": \"When did ALT elevations first become apparent, and how many weeks elapsed before subjects met Hy's Law criteria?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"ALT elevations in the statin subgroup first became apparent during the early signal phase. It took approximately 7-13 weeks from initial detection to subjects meeting Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN) during the escalation phase.\",\n        \"key_facts\": [\n          \"statin_subgroup_alt\",\n          \"cross_site_pattern\",\n          \"alt_temporal_onset\"\n        ],\n        \"evidence\": [\n          \"early_signal:2\",\n          \"early_signal:5\",\n          \"escalation:2\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q08_counterfactual\",\n      \"checkpoint_after\": 25,\n      \"type\": \"counterfactual\",\n      \"prompt\": \"If the Site 07 lab equipment calibration issue were responsible for the ALT elevations, what pattern would you expect across sites? Does that match the data?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"If Site 07 equipment were the cause, ALT elevations would be confined to Site 07 and resolve after recalibration. Instead, the ALT signal appears across multiple sites and correlates with statin co-administration, not site. The cross-site pattern rules out a site-specific equipment explanation.\",\n        \"key_facts\": [\n          \"site07_red_herring\",\n          \"cross_site_pattern\",\n          \"alt_temporal_onset\"\n        ],\n        \"evidence\": [\n          \"red_herring:2\",\n          \"escalation:3\",\n          \"root_cause:2\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q09_longitudinal\",\n      \"checkpoint_after\": 5,\n      \"type\": \"longitudinal\",\n      \"prompt\": \"Based on the first five weeks of trial data, are there any safety signals in the lab panels?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"No. All lab panels are within normal limits across all sites. Hepatic, renal, and hematology markers show no adverse trends. The trial is in the enrollment ramp-up phase.\",\n        \"key_facts\": [],\n        \"evidence\": [\n          \"baseline:3\",\n          \"baseline:5\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q10_evidence\",\n      \"checkpoint_after\": 5,\n      \"type\": \"evidence_sufficiency\",\n      \"prompt\": \"Is there sufficient data at this point to evaluate the safety profile of LNS-4821?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"No. Only 5 weeks of data from the enrollment ramp phase are available. The subject population is too small and exposure duration too short to draw conclusions about the drug's safety profile.\",\n        \"key_facts\": [],\n        \"evidence\": [\n          \"baseline:3\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q11_longitudinal\",\n      \"checkpoint_after\": 20,\n      \"type\": \"longitudinal\",\n      \"prompt\": \"What is the emerging safety profile of LNS-4821, and which patient subgroup is most affected?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"Hepatotoxicity in the statin co-administered subgroup. ALT elevations reaching 2-3x ULN across multiple sites, with two subjects meeting Hy's Law criteria. Non-statin patients remain stable. The cross-site distribution rules out the Site 07 equipment hypothesis.\",\n        \"key_facts\": [\n          \"statin_subgroup_alt\",\n          \"cross_site_pattern\",\n          \"ddi_mechanism\",\n          \"site07_red_herring\",\n          \"immune_markers_normal\",\n          \"pain_endpoints_stable\",\n          \"alt_temporal_onset\",\n          \"renal_function_normal\"\n        ],\n        \"evidence\": [\n          \"escalation:2\",\n          \"escalation:3\",\n          \"escalation:4\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q12_severity\",\n      \"checkpoint_after\": 20,\n      \"type\": \"severity_assessment\",\n      \"prompt\": \"How would you assess the severity of the hepatic signal and the urgency of protocol intervention?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"High severity. Two subjects have met Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN), which is a recognized indicator of potential drug-induced liver injury. The signal is escalating and protocol amendment is urgent to prevent further SAEs.\",\n        \"key_facts\": [\n          \"statin_subgroup_alt\",\n          \"ddi_mechanism\",\n          \"renal_function_normal\",\n          \"immune_markers_normal\",\n          \"pain_endpoints_stable\",\n          \"cross_site_pattern\",\n          \"site07_red_herring\",\n          \"alt_temporal_onset\"\n        ],\n        \"evidence\": [\n          \"escalation:2\",\n          \"escalation:4\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q13_paraphrase\",\n      \"checkpoint_after\": 12,\n      \"type\": \"paraphrase\",\n      \"prompt\": \"Are any laboratory parameters trending outside normal limits in specific patient populations?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"ALT values are creeping upward in a subset of patients, specifically those on concomitant statin therapy. The elevations are still below protocol action thresholds but the trend across multiple weeks is notable.\",\n        \"key_facts\": [\n          \"statin_subgroup_alt\",\n          \"cross_site_pattern\",\n          \"alt_temporal_onset\",\n          \"immune_markers_normal\",\n          \"pain_endpoints_stable\"\n        ],\n        \"evidence\": [\n          \"early_signal:2\",\n          \"early_signal:5\"\n        ]\n      },\n      \"variant_of\": \"cs03_q01_longitudinal\"\n    },\n    {\n      \"id\": \"cs03_q14_paraphrase\",\n      \"checkpoint_after\": 25,\n      \"type\": \"paraphrase\",\n      \"prompt\": \"Why is there a difference in liver enzyme levels between patient subgroups?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"A drug-drug interaction between LNS-4821 and concomitant statin therapy via CYP3A4 inhibition causes hepatotoxicity in the statin subgroup. The signal appears across all sites, not just Site 07, ruling out the equipment calibration hypothesis.\",\n        \"key_facts\": [\n          \"statin_subgroup_alt\",\n          \"cross_site_pattern\",\n          \"ddi_mechanism\",\n          \"site07_red_herring\"\n        ],\n        \"evidence\": [\n          \"early_signal:2\",\n          \"escalation:3\",\n          \"root_cause:1\",\n          \"red_herring:2\"\n        ]\n      },\n      \"variant_of\": \"cs03_q03_longitudinal\"\n    },\n    {\n      \"id\": \"cs03_q15_negative\",\n      \"checkpoint_after\": 20,\n      \"type\": \"negative\",\n      \"prompt\": \"Is there evidence of an immune-mediated reaction or immunogenicity issues with LNS-4821?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"No. Immunogenicity markers and antibody responses are not related to the hepatic safety signal. The mechanism is a pharmacokinetic drug-drug interaction via CYP3A4, not an immune-mediated reaction.\",\n        \"key_facts\": [\n          \"immune_markers_normal\",\n          \"ddi_mechanism\"\n        ],\n        \"evidence\": [\n          \"baseline:5\",\n          \"early_signal:4\"\n        ]\n      },\n      \"expected_answer_polarity\": \"negative\"\n    },\n    {\n      \"id\": \"cs03_q16_negative\",\n      \"checkpoint_after\": 25,\n      \"type\": \"negative\",\n      \"prompt\": \"Are there musculoskeletal or pain-related adverse events associated with LNS-4821?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"No. Pain and musculoskeletal endpoints show no drug-related adverse trends. The safety signal is hepatic, confined to the statin co-administered subgroup.\",\n        \"key_facts\": [\n          \"pain_endpoints_stable\",\n          \"statin_subgroup_alt\"\n        ],\n        \"evidence\": [\n          \"baseline:6\",\n          \"early_signal:5\"\n        ]\n      },\n      \"expected_answer_polarity\": \"negative\"\n    },\n    {\n      \"id\": \"cs03_q17_temporal\",\n      \"checkpoint_after\": 20,\n      \"type\": \"temporal\",\n      \"prompt\": \"How rapidly are ALT values escalating in the affected subgroup?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"ALT values in the statin subgroup have progressed from baseline normal (15-35 U/L) through subtle elevation (45-65 U/L) to clinically significant levels (80-120 U/L, 2-3x ULN) over the course of the signal and escalation phases. The rate of increase has accelerated.\",\n        \"key_facts\": [\n          \"statin_subgroup_alt\",\n          \"ddi_mechanism\",\n          \"alt_temporal_onset\",\n          \"renal_function_normal\",\n          \"pain_endpoints_stable\",\n          \"cross_site_pattern\",\n          \"site07_red_herring\",\n          \"immune_markers_normal\"\n        ],\n        \"evidence\": [\n          \"early_signal:2\",\n          \"escalation:2\",\n          \"escalation:4\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q18_temporal\",\n      \"checkpoint_after\": 15,\n      \"type\": \"temporal\",\n      \"prompt\": \"When did the first hepatic enzyme elevations appear relative to drug exposure initiation?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"Hepatic enzyme elevations first appeared during the early signal phase, approximately weeks 9-10 of the trial, several weeks after subjects began receiving LNS-4821 with concomitant statin therapy.\",\n        \"key_facts\": [\n          \"statin_subgroup_alt\",\n          \"cross_site_pattern\",\n          \"alt_temporal_onset\"\n        ],\n        \"evidence\": [\n          \"early_signal:2\",\n          \"early_signal:5\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q19_distractor\",\n      \"checkpoint_after\": 15,\n      \"type\": \"distractor_resistance\",\n      \"prompt\": \"Are novel urinary biomarkers (KIM-1, NGAL) showing any abnormalities in trial subjects?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"No. Renal biomarkers remain within normal limits. The emerging safety signal is hepatic (ALT/AST elevation), not renal.\",\n        \"key_facts\": [\n          \"renal_function_normal\",\n          \"statin_subgroup_alt\"\n        ],\n        \"evidence\": [\n          \"baseline:4\",\n          \"early_signal:3\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q20_distractor\",\n      \"checkpoint_after\": 25,\n      \"type\": \"distractor_resistance\",\n      \"prompt\": \"Is there any relationship between seroconversion rates and the adverse event pattern?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"No. Immunogenicity measures including seroconversion rates are not related to the hepatotoxicity signal. The adverse events are driven by a CYP3A4-mediated drug-drug interaction with statins.\",\n        \"key_facts\": [\n          \"immune_markers_normal\",\n          \"ddi_mechanism\"\n        ],\n        \"evidence\": [\n          \"baseline:5\",\n          \"root_cause:1\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q21_distractor\",\n      \"checkpoint_after\": 20,\n      \"type\": \"distractor_resistance\",\n      \"prompt\": \"Are VAS pain scores or functional assessments correlating with the laboratory abnormalities?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"No. Pain endpoints are stable and unrelated to the hepatic safety signal. The ALT elevations correlate with statin co-administration, not pain or functional measures.\",\n        \"key_facts\": [\n          \"pain_endpoints_stable\",\n          \"statin_subgroup_alt\"\n        ],\n        \"evidence\": [\n          \"baseline:6\",\n          \"escalation:2\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q22_counterfactual\",\n      \"checkpoint_after\": 20,\n      \"type\": \"counterfactual\",\n      \"prompt\": \"If the ALT elevations were caused by a viral hepatitis outbreak among trial subjects, what pattern would you expect? Does the data match?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"Viral hepatitis would show clustered onset at specific sites, associated symptoms (fatigue, jaundice), and positive viral serologies. Instead, the elevations are distributed across sites and correlate with statin co-administration, not geography or viral exposure. The pattern is consistent with a pharmacokinetic interaction, not infection.\",\n        \"key_facts\": [\n          \"cross_site_pattern\",\n          \"ddi_mechanism\",\n          \"alt_temporal_onset\",\n          \"renal_function_normal\",\n          \"immune_markers_normal\",\n          \"site07_red_herring\",\n          \"pain_endpoints_stable\",\n          \"statin_subgroup_alt\"\n        ],\n        \"evidence\": [\n          \"escalation:3\",\n          \"escalation:4\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q23_null\",\n      \"checkpoint_after\": 20,\n      \"type\": \"null_hypothesis\",\n      \"prompt\": \"How many protocol deviations were reported at Site 03 in the most recent weekly summary?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"The protocol deviation count as documented in the weekly site summary.\",\n        \"key_facts\": [],\n        \"evidence\": [\n          \"escalation:3\"\n        ]\n      }\n    },\n    {\n      \"id\": \"cs03_q24_evidence\",\n      \"checkpoint_after\": 15,\n      \"type\": \"evidence_sufficiency\",\n      \"prompt\": \"Is there sufficient evidence at this point to convene a DSMB safety review?\",\n      \"ground_truth\": {\n        \"canonical_answer\": \"Borderline. The ALT trend in the statin subgroup is concerning but individual values are still below protocol action thresholds. A few more weeks of data showing continued escalation would strengthen the case for DSMB review.\",\n        \"key_facts\": [\n          \"statin_subgroup_alt\",\n          \"cross_site_pattern\",\n          \"ddi_mechanism\",\n          \"site07_red_herring\",\n          \"immune_markers_normal\",\n          \"pain_endpoints_stable\",\n          \"alt_temporal_onset\",\n          \"renal_function_normal\"\n        ],\n        \"evidence\": [\n          \"early_signal:2\",\n          \"early_signal:5\"\n        ]\n      }\n    }\n  ],\n  \"_spec_hash\": \"sha256:18337e265501ea2852bb2f7648860e251703ab998faf12668ece880515dc7b74\"\n}",
  "metadata": {
    "scope_id": "clinical_signal_03",
    "domain": "clinical_notes",
    "layer_name": "spec",
    "layer_level": 0
  }
}